Kyverna Therapeutics Names Christi Shaw Executive Board Chair

Kyverna Therapeutics, Inc. ( (KYTX) ) has provided an update.

Kyverna Therapeutics on January 8, 2026 appointed board member Christi Shaw as Executive Chairperson of the Board, effective January 12, 2026, with former chair Ian Clark remaining on the board. Shaw, a veteran of CAR T commercialization, will receive a $400,000 annual salary and a package of stock options, restricted stock units and performance-based RSUs that vest over four years and are structured to continue vesting if she remains as Board Chairperson or Vice Chairperson after any employment termination, with full vesting acceleration in the event of a change in control. In a corporate update delivered at the J.P. Morgan Healthcare Conference on January 12, 2026, Kyverna highlighted progress in its autoimmune CAR T pipeline, including first patient enrollment in December 2025 in the Phase 3 portion of the KYSA-6 trial of miv-cel in gMG, acceptance in January 2026 of an IND for next-generation candidate KYV-102, and strengthened finances from a December 2025 follow-on offering that extended its cash runway into 2028. The company outlined 2026 priorities centered on filing a Biologics License Application for miv-cel in SPS in the first half of 2026, achieving SPS launch readiness by year-end 2026, advancing the Phase 3 gMG trial and multiple additional autoimmune indications, positioning itself as a potential first commercial provider of CAR T-cell therapy in autoimmune disease and reinforcing its commercialization capabilities through Shaw’s appointment and a fortified balance sheet.

The most recent analyst rating on (KYTX) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Kyverna Therapeutics, Inc. stock, see the KYTX Stock Forecast page.

Spark’s Take on KYTX Stock

According to Spark, TipRanks’ AI Analyst, KYTX is a Neutral.

The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn), partially offset by strong technical uptrend and a favorable slate of recent corporate events (positive trial data plus new financing). Valuation contributes modestly negatively due to the loss-making profile and lack of dividend.

To see Spark’s full report on KYTX stock, click here.

More about Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company developing cell therapies, notably its lead autologous CD19-targeting CAR T-cell candidate miv-cel (mivocabtagene autoleucel, KYV-101), for B‑cell-driven autoimmune diseases. The company is building a potentially first-in-class neuroimmunology franchise with a completed registrational trial in stiff person syndrome (SPS), an ongoing registrational trial in generalized myasthenia gravis (gMG), and additional KYSA and investigator-initiated trials in indications such as multiple sclerosis and rheumatoid arthritis, supported by a next-generation CAR T pipeline aimed at improving patient access and experience.

Average Trading Volume: 1,432,990

Technical Sentiment Signal: Strong Buy

Current Market Cap: $482.7M

For detailed information about KYTX stock, go to TipRanks’ Stock Analysis page.